By Colin Kellaher

 

Atea Pharmaceuticals Inc. on Monday said the U.S. Food and Drug Administration granted fast-track designation to AT-752, its oral antiviral candidate for the treatment of dengue virus infection.

The Boston clinical-stage biopharmaceutical company said AT-752 is in Phase 2 clinical development and was generally well tolerated in a Phase 1 study.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.

Atea said there are no currently approved treatments for dengue, a mosquito-borne viral infection that infects up to 400 million people a year.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

September 26, 2022 07:29 ET (11:29 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Atea Pharmaceuticals Charts.
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Atea Pharmaceuticals Charts.